Trial Profile
OPEN LABEL, PHASE IIA MULTICENTER STUDY OF DASATINIB IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) RELAPSED/REFRACTORY OR NOT AMENABLE TO CONVENTIONAL THERAPY-PTCL-DASA01
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 23 Feb 2018 New trial record